EU Country Coalition Wants New Unmet Needs System To Incentivize The Right Innovation

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

The European Commission’s proposals for legislative reform in the pharmaceutical sector are welcome but must go further to address patient and societal needs, says a coalition of five EU countries dedicated to improving access to medicines.

clinical trials
European Country Coalition Wants To Incentivize Innovation To Meet Unmet Needs • Source: Shutterstock

BeNeLuxA, the cross-country medicines access coalition is calling for a paradigm shift in pharmaceutical innovation from a supply driven system to a “more needs driven model.” The coalition has welcomed the European Commission’s proposals for reforming EU pharmaceutical legislation, but says more needs to be done to ensure patients get the medicines they require, for example by establishing an EU-level system for defining unmet need and using it to incentivize and reward innovation.

Key Takeaways

  • Pharmaceutical innovation should be guided by the needs of society and patients rather than by potential return on investment.

BeNeLuxA is an initiative made up of Belgium, the Netherlands, Luxembourg, Austria and Ireland that aims to improve access to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography